<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997006</url>
  </required_header>
  <id_info>
    <org_study_id>DTH:19001</org_study_id>
    <nct_id>NCT03997006</nct_id>
  </id_info>
  <brief_title>Is Aminophylline More Effective Than Neostigmine/Atropine Mixture in the Treatment of Post-dural Puncture Headache</brief_title>
  <acronym>RCT</acronym>
  <official_title>Is Aminophylline More Effective Than Neostigmine/Atropine Mixture in the Treatment of Post-dural Puncture Headache: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour Teaching Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To compare the safety and efficacy of IV aminophylline versus IV
      neostigmine/atropine mixture in the treatment of post-dural puncture headache (PDPH).

      Background: PDPH is the most frequent complication of procedures associated with dural
      puncture for spinal anesthesia or following accidental dural puncture during epidural
      anesthesia. Since invasive treatments have known complications, pharmacologic management may
      be preferable.

      Patients and Methods: This was a prospective, randomized, double-blind, phase four clinical
      trial; carried out on 60 patients presented with PDPH at our hospital. Patients were randomly
      allocated into two equal groups (30 patients each); group A, received IV aminophylline, and
      group NA, received IV neostigmine/atropine mixture.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median and Range of Numeric Pain Rating Scale (NPRS) score</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>NPRS measures the severity of PDPH, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain (before, 2h, 6h, 12h, then every 12h till 48h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard deviation of PDPH duration (hours) (mean±SD)</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Time from PDPH onset till NPRS score ≤ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants and Rate of Treatment-related complications</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Number of participants and Rate of: Diarrhea, Palpitation, Abdominal cramps, Muscle twitches, Bronchospasm, Urinary bladder hyperactivity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Post-Dural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Group A (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aminophylline group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group NA (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine/Atropine group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Aminophylline</intervention_name>
    <description>IV Aminophylline (100 mg/8h)</description>
    <arm_group_label>Group A (n=30)</arm_group_label>
    <other_name>Minophylline-N ampoule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Neostigmine Methylsulfate + Atropine Sulphate</intervention_name>
    <description>IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h</description>
    <arm_group_label>Group NA (n=30)</arm_group_label>
    <other_name>Neostigmine ampoule, Atropine ampoule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NPRS score of ≥ 5

          -  American Society of Anesthesiologists (ASA) physical status ≤ II

          -  Age from 21 to 50 years

        Exclusion Criteria:

          -  Patients with NPRS score &lt; 5

          -  ASA physical status &gt; II

          -  Age &lt; 21 years or &gt; 50 years

          -  Pregnant women

          -  History of; chronic headache, Cluster headache, Migraine

          -  History of; Convulsions, Cerebrovascular accident, Previous neurological diseases

          -  Signs of meningismus

          -  Bronchial asthma

          -  Arrhythmia

          -  Hypertension

          -  Ischemic heart disease

          -  Hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Shaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour Teaching Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Damanhour Teaching Hospital</name>
      <address>
        <city>Damanhūr</city>
        <state>El-Beheira</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aminophylline</keyword>
  <keyword>Atropine</keyword>
  <keyword>Neostigmine</keyword>
  <keyword>Post-dural puncture headache</keyword>
  <keyword>Spinal anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Aminophylline</mesh_term>
    <mesh_term>Acefyllin piperazinate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

